Gambia tightens quality checks on medicines from India
Gamia's drug regulator introduces regulation of pre-shipment document verification, physical inspection, quality control testing, issuance of CRIA for pharmaceuticals
Gamia's drug regulator introduces regulation of pre-shipment document verification, physical inspection, quality control testing, issuance of CRIA for pharmaceuticals
Advisory comes after deaths were reported from Uzbekistan, Gambia after kids consumed cough syrups with high levels of diethylene glycol and ethylene glycol supplied by Indian manufacturers
CDSCO in its December 2022 alert says five cough syrup samples produced by Maiden at its Baddi plant are "not of standard quality".
CDSCO along with UP Drug Control Administration had carried out a joint inspection of Marion's Noida facility, says health minister Mansukh Mandaviya.
Uzbekistan is the second country after Gambia to link child deaths to India made cough syrups.
The Drugs Controller General of India (DCGI) has ruled out contamination possibilities in the four products Maiden Pharma supplied to Gambia.
Maiden Pharmaceutical holds manufacturing permission for these products for export only, the government says.